GLP-1s in 2026
June 29, 2026
Few classes of medication have moved from breakthrough to mainstream to inflection point as quickly as GLP-1 receptor agonists. In just a few years, Ozempic, Wegovy, Mounjaro, and Zepbound have reshaped how the medical community talks about obesity, diabetes, cardiovascular risk, and increasingly addiction. They've also reshaped the conversations happening at kitchen tables, in HR offices, and across the desks of family caregivers trying to figure out how to keep a loved one on a therapy that may genuinely change the trajectory of their health.
In 2026, the landscape is being rewritten in real time. Regulators are clearing oral formulations that didn't exist eighteen months ago. Researchers are publishing evidence that these drugs may quiet the cravings of substance use disorders the way they quiet appetite. Pricing structures that put these medications out of reach for years are collapsing under federal and direct-to-consumer pressure. National health systems abroad are testing different models, with different consequences for the patients they serve. Newer variations of these types of drugs are in development and are undergoing clinical trials that also show real promise of even greater efficacy. GLP-1s appear in the news on a daily basis in multiple ways!
This is not a moment for passive consumption of headlines. It's a moment that demands a sharper kind of advocacy, from clinicians, caregivers, family members, and patients themselves. The right questions to ask in 2026 are not the same as the right questions to ask in 2024. What follows is a framework for the four shifts that matter most, and what each one requires of the people responsible for someone else's outcome.
The injectable was always a barrier to entry. For every patient who started a GLP-1, others stalled at the threshold due to needle anxiety, schedule disruption, the need to refrigerate the medication, the weekly ritual that quietly wore them down. These barriers are now coming down.
In December 2025, the FDA approved the first oral GLP-1 specifically for weight management, once-daily Wegovy (semaglutide 25 mg). Novo Nordisk launched it in U.S. pharmacies in early January 2026. The clinical foundation is substantial: in the OASIS 4 trial, fully adherent patients on oral semaglutide 25 mg lost an average of 16.6% of body weight at 64 weeks, compared with 2.7% on placebo. Demand has exceeded forecasts, Novo reported more than 600,000 prescriptions for the pill in March alone, and the company has indicated the launch is expanding the obesity treatment market rather than converting existing injection users.
A second pill followed in April 2026: Eli Lilly's orforglipron, marketed as Foundayo. Its differentiator is convenience; it can be taken any time of day without food or water restrictions, which is not true of the Wegovy pill, and which offers an advantage that matters more in real-world adherence than the trial-data debates suggest.
The question to focus on is not "pill or injection?" That's a marketing frame. The primary question is adherence. The best GLP-1 for any individual patient is the one they will take consistently for the years it takes to deliver durable benefit. That answer depends on schedule, GI history, swallowing comfort, travel patterns, caregiver bandwidth, and what the patient actually wants their morning routine to look like. Side-by-side comparisons of the pill and injection options are useful inputs, but reframing the prescribing conversation around adherence, rather than around delivery method, is one of the most useful things an advocate can do at the start of therapy.
A note on what the pill does not change: it is not a milder medication. The side effect profile (nausea, GI distress, gallbladder concerns) tracks with the injectable. Patients deserve to hear that clearly before day one.
Few topics in the GLP-1 conversation have generated more public concern, and more uneven coverage, than the question of muscle loss. A clear-eyed reading of the evidence supports neither alarm nor dismissal. It supports planning.
The first thing to know: the mechanism is not unique to GLP-1s. Any rapid weight loss reduces a mix of fat, water, organ tissue, bone, and muscle. Mass General Brigham researchers, in a recent Medical Grand Rounds review of the evidence, emphasized that weight loss paradigms universally induce the loss of lean body mass, not just GLP-1s. A 2024 meta-analysis of 22 randomized controlled trials found that lean mass loss comprises approximately 25% of total weight lost across the GLP-1 drug class, with some semaglutide trials reporting lean mass losses of up to 40% of total weight lost, muscle, organ tissue, and bone bundled together. More recent analyses have moderated that picture: some 2025–2026 data suggest that GLP-1-induced weight loss reduces absolute lean mass without disproportionately stripping muscle relative to fat, particularly in middle-aged adults.
A second point that is often missed in public coverage: the Mass General clinicians note that a measured decrease in lean body mass does not necessarily mean the functional status of the muscle is worse. As they framed it, some lean body mass loss is part of any successful weight-loss journey. The takeaway across both readings of the literature is consistent: muscle preservation should be designed into the therapy plan from the start. That does not mean GLP-1s are a poor choice. It means the surrounding plan matters.
The stakes are not cosmetic. Muscle is metabolic infrastructure. It supports balance, bone density, blood sugar regulation, and the day-to-day capacity to live independently. A year of weight loss without muscle preservation can shorten the runway of independence by years on the back end, a tradeoff most patients would not knowingly accept if it were clearly explained at the outset. Taking the right preservation steps matters; the use of GLP-1 therapy itself is not the problem.
The literature has converged on a fairly stable protocol:
A practical best approach: insist on body-composition tracking, not just weight or BMI (Body Mass Index). A DEXA scan or a quality bioelectrical impedance reading at baseline and every six months tells a fuller story, though the Mass General clinicians also note that more accurate tools for measuring body composition and muscle function are still needed, and this remains an active area of research. The bathroom scale is, at this point, an inadequate instrument for measuring success on this drug class.
A wave of research is also underway into pharmacologic adjuncts designed specifically to preserve lean mass during GLP-1 therapy. This area is hotly debated in terms of how much added benefit such adjuncts will offer beyond protein and exercise, and the next few years will produce some interesting discussions on that question.
The most consequential research signal in the GLP-1 field right now is not about weight. It is about the brain's reward system.
Patients on GLP-1s began reporting something unexpected: cravings for alcohol, cigarettes, cocaine, gambling, even compulsive online shopping had dimmed. Researchers chasing that signal have found it repeatedly. The biological logic is sound, GLP-1 receptors are present in the brain's reward circuitry, and modulation of dopamine signaling appears to dial down the urgency of compulsive behaviors broadly, not just food.
The 2026 evidence base, in summary:
What the evidence does not yet support: FDA approval for any addiction indication. As of February 2026, the FDA has not approved GLP-1s for the treatment of addiction. Off-label prescribing is occurring, particularly when a patient also qualifies for an approved use, but this is a frontier, not a settled standard of care. For many patients in the mental health and/or addiction space, their medications for treating those disorders already contribute significantly to weight gain too, which may help to qualify them for the approved categories for GLP-1 use.
The honest negatives matter here. GLP-1s are not a substitute for the proven scaffolding of recovery, counseling, peer support, medication-assisted treatment with buprenorphine or naltrexone where indicated. They may be an addition, not a replacement. The side effect profile (nausea, fatigue, gallbladder issues) can complicate early recovery, when stability matters most. And insurance coverage for an addiction indication is not on the near-term horizon, which raises serious access questions for the families who tend to need help most urgently.
At this juncture, leaders in this field of research espouse restraint. The promise is real and worth tracking carefully. But sound advocacy means insisting on clinical trial pathways where they exist, refusing to let GLP-1 prescribing replace the rest of the recovery infrastructure, and ensuring that families understand what is established and what is still being assembled. One other reasonable concern is that addiction and eating disorders have a fairly high percentage of concurrence (the percentage varies by type of eating disorder). Therefore use of GLP-1s need to be carefully considered in the context of the patient’s whole set of diagnoses and life experiences to make sure that other issues will not be triggered.
For most of the past several years, the GLP-1 story was an access story. List prices in the $1,000–$1,350 per month range put these drugs out of reach for the majority of patients who would have benefited, including many whose lives would be measurably extended by them.
In 2026, that math is changing. Imperfectly, but meaningfully.
The TrumpRx platform launched in early 2026 as a direct-to-consumer route built around "Most-Favored-Nation" pricing agreements with Eli Lilly and Novo Nordisk. As of this writing, publicly listed prices include:
For Medicare beneficiaries, manufacturers agreed to price injectable Ozempic, Mounjaro, Wegovy, and Zepbound at $245 per month for Medicare across all doses and indications, with a $50 monthly copay cap for eligible enrollees. The Medicare access pathway for obesity (the "BALANCE" Bridge) has had a complicated rollout, the Part D insurer-based component was canceled following insurer pushback, with the federal government now funding the program directly outside standard Part D, but the patient-facing $50 copay goal remains in place.
The honest caveats that often go unmentioned in the headline coverage:
The best choice here is to remain flexible and not to recommend a single channel. It is to insist that the access question be reassessed at every refill, every plan year, and every life transition. The right answer is patient-specific and time-sensitive.
Recent studies are pointing to the possibility that GLP-1s may have a positive influence on reducing cancer risk for certain cancers. Initial research points especially to the potential in the areas of endometrial, ovarian and meningioma cancers. These need more investigation but it is exciting nonetheless as well as exploring the possible positives (and negatives) with other cancers. Other studies have shown correlational relationships between use of GLP-1s and reduction of other cancers including breast, liver, colorectal and non-small cell lung cancer. Some of this may be related to reduction in weight or other factors because not all of the cancer types are generally associated with obesity. More study is needed.
The U.S. is not alone in working through these decisions, and there is real value in studying how other systems are handling them.
The United Kingdom rations NHS access through clinical eligibility tiers. The Obesity Health Alliance and NHS projections suggest fewer than 50,000 people per year will receive semaglutide by 2028 against an eligible population of roughly 4.1 million. Concerns about widening health inequalities are openly debated by the Royal College of Physicians. The lesson: rationing without robust private-pathway support can entrench rather than reduce health disparities.
Denmark has approved both Wegovy and Saxenda for obesity treatment, and public healthcare may pay for severe obesity with significant comorbidities. Denmark strongly encourages combining GLP-1 treatment with structured lifestyle support, supervised diet, exercise, and behavioral programs. The lesson: wraparound care is not a supplement to medication. It is the model.
France offers limited public coverage that can be supported by referral from a GP to an obesity specialist or center. The lesson: a defined specialist pathway helps ensure the right patients receive the medication for the right indications.
Norway, Spain, and Italy have historically limited public reimbursement for obesity-indication GLP-1s, with most patients paying privately.
The pattern across high-income countries is unmistakable. Every system has had to balance enormous demand against drug cost and capacity. The systems producing the most durable patient outcomes are not necessarily the ones with the most generous coverage. They are the ones pairing medication access with structured nutrition, exercise, behavioral support, and follow-up care. That model is the one to build toward in any individual treatment plan, regardless of which payer is footing the bill.
A framework for anyone responsible for guiding a patient's path forward in 2026:
The GLP-1 conversation is often no longer about whether a patient should start one. It is about which one, delivered how, with what support, and paid for through which channel. Those are the decisions that determine whether this generation of medications fulfills its potential, or whether it becomes another chapter in the long story of breakthrough therapies that worked best for the patients who needed them least.
Good advocacy means making sure those questions are answered well in advance, so that when the moment to decide arrives, no one is deciding under pressure. It is a complex but meaningful question on an important frontier for health!
.svg){kind=small}
Disclaimer: The contents of HealthACR Insights are intended to provide information we hope you find interesting, timely and useful. We carefully research the topics using reliable, highly regarded sources. Citations are provided. We in no way intend to offer clinical advice that you should use to make treatment decisions. Please consult appropriate professionals. HealthACR, LLC is available to help you identify potential options and find providers to meet your needs.
